-+ 0.00%
-+ 0.00%
-+ 0.00%

Lenz Therapeutics submits UK MHRA marketing application for VIZZ presbyopia eye drop

PUBT·04/20/2026 12:02:29
Listen to the news
Lenz Therapeutics submits UK MHRA marketing application for VIZZ presbyopia eye drop
  • Lenz Therapeutics submitted Marketing Authorization Application to UK MHRA seeking approval of VIZZ (aceclidine ophthalmic solution) 1.44% for presbyopia in adults.
  • Filing follows EMA validation of VIZZ Marketing Authorization Application in March 2026.
  • VIZZ received FDA approval in July 2025.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lenz Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604200800PRIMZONEFULLFEED9692713) on April 20, 2026, and is solely responsible for the information contained therein.